Marketing-authorisation holder
Gilead Sciences, Inc.
32 medicines in 2 countries, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder
32 medicines in 2 countries, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 32
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ATRIPLA600MG; 200MG; 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Efavirenz, Emtricitabine, Tenofovir disoproxil | United States | Not marketed | 2006 |
| BIKTARVY30mg base; 120mg; 15mg base | 50mg base; 200mg; 25mg base · Tablet | Bictegravir, Emtricitabine, Tenofovir alafenamide | United States | Marketed | 2018 |
| COMPLERA200mg; 25mg base; 300mg · Tablet | Emtricitabine, Rilpivirine, Tenofovir disoproxil | United States | Marketed | 2011 |
| DESCOVY120mg; 15mg base | 200mg; 25mg base · Tablet | Emtricitabine, Tenofovir alafenamide | United States | Marketed | 2016 |
| EPCLUSA150mg; 37.5mg/packet | 200mg; 50mg/packet · Pellets | Sofosbuvir, Velpatasvir | United States | Marketed | 2021 |
| EPCLUSA200mg; 50mg | 400mg; 100mg · Tablet | Sofosbuvir, Velpatasvir | United States | Marketed | 2016 |
| GENVOYA150mg; 150mg; 200mg; 10mg base · Tablet | Cobicistat, Elvitegravir, Emtricitabine, Tenofovir alafenamide | United States | Marketed | 2015 |
| HARVONI33.75mg; 150mg/packet | 45mg; 200mg/packet · Pellets | Ledipasvir, Sofosbuvir | United States | Marketed | 2019 |
| HARVONI45mg; 200mg | 90mg; 400mg · Tablet | Ledipasvir, Sofosbuvir | United States | Marketed | 2014 |
| HEPCLUDEX8.5mg · Injection | Bulevirtide | United States | Marketed | 2026 |
| LIVDELZI10mg base · Capsule | Seladelpar | United States | Marketed | 2024 |
| ODEFSEY200mg; 25mg base; 25mg base · Tablet | Emtricitabine, Rilpivirine, Tenofovir alafenamide | United States | Marketed | 2016 |
| SOVALDI150mg/packet | 200mg/packet · Pellets | Sofosbuvir | United States | Marketed | 2019 |
| SOVALDI200mg | 400mg · Tablet | Sofosbuvir | United States | Marketed | 2013 |
| STRIBILD150mg; 150mg; 200mg; 300mg · Tablet | Cobicistat, Elvitegravir, Emtricitabine, Tenofovir disoproxil | United States | Marketed | 2012 |
| SUNLENCA300mg base · Tablet | Lenacapavir | United States | Marketed | 2022 |
| SUNLENCA463.5mg base/1.5ml (eq 309mg base/ml) · Solution | Lenacapavir | United States | Marketed | 2022 |
| TYBOST150mg | 90mg · Tablet | Cobicistat | United States | Not marketed | 2014 |
| VEKLURY100mg/vial · Powder | Remdesivir | United States | Marketed | 2020 |
| VEKLURY100mg/20ml (5mg/ml) · Solution | Remdesivir | United States | Not marketed | 2020 |
| VEMLIDY25mg base · Tablet | Tenofovir alafenamide | United States | Marketed | 2016 |
| VIREAD150mg | 200mg | 250mg | 300mg · Tablet | Tenofovir disoproxil | United States | Marketed | 2001 |
| VIREAD40mg/scoopful · Powder | Tenofovir disoproxil | United States | Marketed | 2012 |
| VISTIDE375MG BASE/5ML (EQ 75MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution | Cidofovir | United States | Not marketed | 1996 |
| VITEKTA150mg | 85mg · Tablet | Elvitegravir | United States | Not marketed | 2014 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 30 | 30 | 0 | CompaniesAll medicines |
| Saudi Arabia | 2 | 2 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.